TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03621267

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interactive Stepping Exercise
Description: Interactive Stepping Exercise will perform on a thin mat, stepping pattern will display through a monitor screen, immediate auditory feedback will give for adjustment

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Home exercise program
Description: Home exercise program includes stretching exercise, general strengthening exercise on lower extremity muscles, posture control and balance exercise.
Study: NCT03686124

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IMADetect®
Description: IMADetect® is developed as a companion diagnostic to aid in selecting patients with relapsed and/or refractory solid cancers who might be eligible for enrollment in Immatics
Study: NCT03100825

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QVM149
Description: QVM149 (indacaterol acetate/glycopyrronium bromide/mometasone furoate)
Study: NCT00436280

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: enzastaurin
Description: 1125 mg loading dose then 500 mg, oral, daily, until disease progression or 3 years

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine
Description: 1000 mg/m², IV, once, every two weeks, four to eight 2 week cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rituximab
Description: 375 mg/m², IV, once every 2 weeks, four to eight 2 week cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Description: 100 mg/m², IV, once every two weeks, four to eight 2 week cycles
Study: NCT03328689

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical activity program
Description: This arm will begin with PT assessment. Following this, participants will meet with a specialist who will design an individualized physical activity program. Classes will include warm up, 40 minutes of individualized exercises and a cool down that will include back pain specific exercises including core strengthening. The first 4 weeks of exercise will include a 30-minute education program. Education comprise information on back pain, efficient use of the back during daily activities, self-management, self-efficacy and pain neurophysiology. Classes will run for a 12-week period. Participants will be encouraged to attend the exercise facility at least 3 times a week. An activity monitor will be provided to all participants. We will use group classes to facilitate the development of social support.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control group standard care
Description: Participants from the control group will receive usual care which will often include recommendation to keep activity, home exercise programs and advice to engage in physical activity.~Participants in the control group will also receive and activity monitor for collection of physical activity data. This activity monitor may also be used for positive feedback and activity reinforcement
Study: NCT02690285

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dichloroacetate (DCA)
Description: Dichloroacetate (DCA) 25 mg/kg oral solution will be administered daily for 5 days.

Intervention type: OTHER
Group type: OTHER
Intervention: GSTZ1 haplotyping
Description: One teaspoon of blood is collected by standard phlebotomy. Cheek cells are collected by standard brushing. Samples will be analyzed at two independent laboratories to validate methods for GSTZ1 haplotype analysis.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: GSTZ1 haplotyping
Description: One teaspoon of blood is collected by standard phlebotomy. Cheek cells are collected by standard brushing. Samples will be analyzed at two independent laboratories to validate methods for GSTZ1 haplotype analysis.
Study: NCT04448470

Intervention type: OTHER
Intervention: Questionnaire for recording daytime sleepiness over the course of the day
Description: Questionnaire for recording daytime sleepiness over the course of the day

Intervention type: OTHER
Intervention: Questionnaire for recording daytime sleepiness over the course of the day
Description: Questionnaire for recording daytime sleepiness over the course of the day

Intervention type: OTHER
Intervention: Anamnesis and physicial examination
Description: Anamnesis and physical examination, e.g. medication, comorbidities, complaints

Intervention type: OTHER
Intervention: Anamnesis and physicial examination
Description: Anamnesis and physical examination, e.g. medication, comorbidities, complaints

Intervention type: OTHER
Intervention: Questionnaire for quantifying daytime sleepiness
Description: the Epworth Sleepiness Scale (ESS) questionnaire and the STOP BANG Questionnaire

Intervention type: OTHER
Intervention: Questionnaire for quantifying daytime sleepiness
Description: the Epworth Sleepiness Scale (ESS) questionnaire and the STOP BANG Questionnaire

Intervention type: DIAGNOSTIC_TEST
Intervention: Pulmonary function test
Description: The measured values of spirometry/body plethysmography, CO diffusion and blood gas analysis are documented, if available.

Intervention type: DIAGNOSTIC_TEST
Intervention: Pulmonary function test
Description: The measured values of spirometry/body plethysmography, CO diffusion and blood gas analysis are documented, if available.

Intervention type: DIAGNOSTIC_TEST
Intervention: Polygraphy
Description: Polygraphy is a non-invasive portable examination method that the patient uses in the home environment at night to measure possible sleep-related breathing disorders. Typically, the following measurement signals are recorded: nasal airflow, thoracic and abdominal breathing excursions, snoring and breathing sounds via a microphone, pulse, oxygen saturation and position. The evaluation results and the findings are checked by a physician. Essential parameters include the apnoea-hypopnoea index, the number of obstructive, central and mixed apnoea/hypopnoea, the number and duration of desaturation, snoring or the association with a certain position.

Intervention type: DIAGNOSTIC_TEST
Intervention: Polygraphy
Description: Polygraphy is a non-invasive portable examination method that the patient uses in the home environment at night to measure possible sleep-related breathing disorders. Typically, the following measurement signals are recorded: nasal airflow, thoracic and abdominal breathing excursions, snoring and breathing sounds via a microphone, pulse, oxygen saturation and position. The evaluation results and the findings are checked by a physician. Essential parameters include the apnoea-hypopnoea index, the number of obstructive, central and mixed apnoea/hypopnoea, the number and duration of desaturation, snoring or the association with a certain position.
Study: NCT01947530

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Navigational Bronchoscopy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Navigational Bronchoscopy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Bronchoscopy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Bronchoscopy
Study: NCT01511380

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Risk Reduction Therapy for Adolescents
Description: This project integrates CM and a family systems intervention for sexual risk with evidence-based family engagement strategies, and tests this intervention in a juvenile drug court setting. Due to the individualized nature of the proposed intervention, the specific course of treatment will vary by youth and family. Based on our experience with clinic-based treatment models it is anticipated that most families will remain in active treatment for 4-6 months and that, during this time, they will attend approximately 1-2 sessions per week, for 1-2 hours per session.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual services
Description: In addition to the standard juvenile drug court requirements, youth randomly assigned to the usual services condition are also ordered to receive treatment services from the local state or privately-funded alcohol and drug treatment provider agencies. The service delivery model for agencies typically includes intensive outpatient, traditional outpatient, and home-based services, depending upon assessment of youth and family needs. Groups focus on risk reduction, peer influence, conflict resolution, and anger management. Additionally, youth might receive treatment pertaining to drug selling behavior, individual sessions and/or family group therapy. The theoretical orientations of the provider agencies are cognitive-behavioral and systems theory. Interventions are not usually manual driven, and selection of material is typically left to the therapists' discretion.
Study: NCT00967408

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Escitalopram
Description: Rehabilitative treatment + Oral Escitalopram 5 mg/day for the first week, 10 mg/day from second to fourth week and 20 mg/day until 6th month.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Rehabilitative treatment + oral inactive placebo for 6 months

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rehabilitative treatment
Description: Rehabilitative treatment

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Rehabilitative treatment
Description: Rehabilitative treatment
Study: NCT00153751

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Traditional Chinese Medicine
Description: They are Common peony root, Rhizoma Atractylodis Macrocephalae, Radix Paeoniae Lactiflorae, Cortex Magnoliae Officinalis, Rhizoma Curcumae Longae, Fructus Schisandrae Chinensis, Pericarpium Citri Reticulatae, and Rhizoma Corydalis Yanhusuo.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Holopon
Description: holopon

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study: NCT01757418

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Immune Globulin Intravenous (IVIG)
Description: A single dose of intravenous immune globulin or saline placebo administered within 24 hours of hospital presentation. The maximum dose in Phase I was 800 mg/kg. The dose for Phase II is 400mg/kg.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: A single dose of normal saline administered within 24 hours of hospital admission for uncomplicated pain crisis.
Study: NCT01504074

Intervention type: BEHAVIORAL
Intervention: if needed (decided individually) either Acular eye drops, Ultracortenol eye drop or intravitreal triamcinolone injection
Description: if prescribed: Ultracortenol/ Acular eye drops 3-4 times a day, if prescribed: singular intravitreal triamcinolone injection
Study: NCT02163746

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CO2 (carbon dioxide) laser
Study: NCT00751088

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TVT secur system positioning
Description: Patient placed in lithotomic position. 1.5 cm incision made, starting 1 cm down to the urethral meatus. Tunneling wide to 12-15 mm up to the bonny edge horizontally to the inferior pubic arm by spreading the scissors blades while withdrawing it, at a plane parallel to the vaginal wall. Mucosal undermining performed at the level of the upper and lower frenulum attaching the sub-urethral tissue to the vaginal wall. Insertion of the device to the bonny edge, horizontaly to the inferior pubic arm, and behind the bone edge to the internal obturator muscle. TVT Secur System will be placed by means of two curved, stainless steel, single use introducers. Incision closure.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ajust positioning
Description: Patient placed in lithotomic position. 1.5 cm incision made, starting 1 cm down to the urethral meatus. Tunneling wide to 12-15 mm up to the bonny edge horizontally to the inferior pubic arm by spreading the scissors blades while withdrawing it, at a plane parallel to the vaginal wall. Mucosal undermining performed at the level of the upper and lower frenulum attaching the sub-urethral tissue to the vaginal wall. Insertion of the device to the bonny edge, horizontaly to the inferior pubic arm, and behind the bone edge to the internal obturator muscle. Ajust will be placed by means of a safe hook geometry introducer. Incision closure.
Study: NCT02163746

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgical Deroofing
Study: NCT03294382

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A
Description: 5U botulinum toxin in 0.1 mL normal saline, injected in two points at one side, 2.5U per point, local injection
Study: NCT00211081

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spironolactone (drug)
Description: 1 mg/kg/day; afer 2 weeks doubled to 2/mg/kg/day. Patient's with endothelium-dependent brachial artery vasodilation and single-ventricle should show improvement within 4-8 weeks. Patients and their labs who are receiving Spironolactone will be followed.
Study: NCT00402389

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omega-3 Fatty Acids (EPA plus DHA)
Description: Four capsules will be taken daily for 8 weeks.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Supportive psychotherapy
Description: Supportive psychotherapy will provide education to increase understanding of the condition, guidance on how to cope with depression, and methods on how to improve self-esteem.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Supportive psychotherapy
Description: Supportive psychotherapy will provide education to increase understanding of the condition, guidance on how to cope with depression, and methods on how to improve self-esteem.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Four capsules will be taken daily for 8 weeks.
Study: NCT03294382

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.1 mL normal saline, injected in two points at one side, 0.05 mL per point, local injection
Study: NCT01150695

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Normal saline will be administered to all subjects as a control and will be given at the same visit as the vaccine (Day 0).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Normal saline will be administered to all subjects as a control and will be given at the same visit as the vaccine (Day 0).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Undiluted Francisella tularensis live attenuated vaccine
Description: Undiluted Francisella tularensis live attenuated vaccine \[approximately 1x10\^9 colony forming units (cfu)/mL\] produced by Dynport Vaccine Company. Administered by scarification in the ulnar aspect of the volar surface (palm side) of the forearm midway between the wrist and the elbow.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Undiluted Francisella tularensis live attenuated vaccine
Description: Undiluted Francisella tularensis live attenuated vaccine (approximately 1x10\^9 cfu/mL) in use by the United States Army Medical Research Institute of Infectious Diseases. Administered by scarification in the ulnar aspect of the volar surface (palm side) of the forearm midway between the wrist and the elbow.
Study: NCT00678691

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: armodafinil
Description: 50-250mg/d
Study: NCT02674568

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rovalpituzumab tesirine
Description: Rovalpituzumab tesirine is a DLL3 targeted antibody drug conjugate (ADC).
Study: NCT00678691

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: matching placebo
Study: NCT01689896

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Testosterone Gel

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Gel
Study: NCT02260427

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Insertion of the i-gel
Description: After induction of general anesthesia, the i-gel will be inserted according to randomly allocated group.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Insertion of the air-Q sp
Study: NCT03765307

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SyMap Bronchial Ablation System
Description: The Bronchial Ablation is performed using SyMap Bronchial Ablation System in three sessions at least three weeks apart between each session: Right Lung Lobe, Left Lung Lobe, Right Up Lobe and Left Up Lobe.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Boston Scientific Alair System
Description: The Bronchial Thermoplasty is performed using Boston Scientific Alair System in three sessions at least three weeks apart between each session: Right Lung Lobe, Left Lung Lobe, Right Up Lobe and Left Up Lobe.
Study: NCT02017691

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Near Infrared Spectroscopy
Description: If crSO2 is \<10th centile, CPAP via face mask will be started or oxygen support will be increased depending SpO2, on the infants breathing efforts and the heart rate. If crSO2 remains stable \>10th centile, or if crSO2 is \> 90th centile CPAP via face mask will be stopped or FiO2 will be reduced depending on SpO2, the infants breathing efforts and the heart rate.

Intervention type: DEVICE
Group type: OTHER
Intervention: Pulse-oximetry
Description: If SpO2 remains \<10th centile, respiratory support via face mask will be started or FiO2 will be increased depending on the infants breathing efforts and the heart rate. If SpO2 remains stable or if SpO2 is \>90th centile respiratory support via face mask will be stopped or FiO2 will be reduced depending on the infants breathing efforts and the heart rate.
Study: NCT03623737

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: neoadjuvant chemoradiation
Description: Neoadjuvant chemoradiation:~1. Radiation: 180cGy/fraction, once daily, 5 days a week, to a total of 4,500cGy.~2. Chemotherapy: Arm A or Arm B Surgery: esophagectomy and 3-fields lymph node dissection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: neoadjuvant chemoradiation
Description: Neoadjuvant chemoradiation:~1. Radiation: 180cGy/fraction, once daily, 5 days a week, to a total of 4,500cGy.~2. Chemotherapy: Arm A or Arm B Surgery: esophagectomy and 3-fields lymph node dissection
Study: NCT03552887

Intervention type: PROCEDURE
Intervention: Cardiac Surgery
Description: Any type of cardiac surgery

Intervention type: PROCEDURE
Intervention: Physiotherapy
Description: Any type of physiotherapy intervention, performed by physiotherapists outside of the protocol
Study: NCT02601040

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Attenuated Hepatitis A Vaccine, H2 Strain
Description: 6.50 lgCCID50/ml in babies aged 18-35 months\\6.50 lgCCID50/ml in children aged 3-16 years \\6.50 lgCCID50/ml in adults aged 17 up to 65 years old

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inactivated Hepatitis A Vaccine, Lu8 Strain
Description: 320EU/Vial in babies aged 18-35 months \\320EU/Vial in children aged 3-16 years \\640EU/Vial in adults aged 17 up to 65 years old\\boost at month 6\\two-dose

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Group A Meningococcal Polysaccharide vaccine
Description: 30µg Group A Meningococcal Polysaccharide vaccine in subjects aged 18 months-65 years old
Study: NCT04029766

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HSK3486
Study: NCT02928562

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercise
Description: cyclic exercise, aerobic exercise and resistant training exercise
Study: NCT02826239

Intervention type: DEVICE
Intervention: multiple breath washout test (MBW)
Description: measured in upright and supine position

Intervention type: DEVICE
Intervention: multiple breath washout test (MBW)
Description: measured in upright and supine position
Study: NCT01285388

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MB12066
Description: MB12066 10mg, 100mg/tab. once oral dose MB12066 10, 30, 100, 150, 200mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MB12066
Description: MB12066 10mg, 100mg/tab. once oral dose MB12066 10, 30, 100, 150, 200mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MB12066
Description: MB12066 10mg, 100mg/tab. once oral dose MB12066 10, 30, 100, 150, 200mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MB12066
Description: MB12066 10mg, 100mg/tab. once oral dose MB12066 10, 30, 100, 150, 200mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MB12066
Description: MB12066 10mg, 100mg/tab. once oral dose MB12066 10, 30, 100, 150, 200mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: MB12066
Description: MB12066 10mg, 100mg/tab. once oral dose MB12066 10, 30, 100, 150, 200mg
Study: NCT04285736

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivabradine
Description: Ivabradine (5mg twice daily)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ivabradine
Description: Ivabradine (5mg twice daily)
Study: NCT00654524

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gonadotropin-releasing-hormone agonist (GnRHa) - Goserelin
Description: The patient will be managed with GnRH-a injection (Goserelin 3.6mg) every 4 weeks for 6 months plus add-back therapy (Caltrate With Vitamin D 600mg p.o. q.d.\& Livial 1.25-2.5mg p.o. q.d.) if needed.
Study: NCT04285736

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Treatment
Study: NCT01890200

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Peginterferon alfa-2a
Description: conventional treatment of Hepatitis C

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon alfa-2a
Description: conventional treatment of Hepatitis C

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon alfa-2a
Description: conventional treatment of Hepatitis C

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ribavirin
Description: conventional treatment of Hepatitis C

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: conventional treatment of Hepatitis C

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: conventional treatment of Hepatitis C

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TCM-700C
Description: An add-on drug to conventional treatment of Hepatitis C

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TCM-700C
Description: An add-on drug to conventional treatment of Hepatitis C

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, without acting ingredient.
Study: NCT00779766

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HPV GSK 580299 vaccine
Description: Subjects were planned to receive three doses of the study vaccine administered intramuscularly according to a 0, 1, 6 month vaccination schedule.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo control
Description: Subjects were planned to receive three doses of the placebo control administered intramuscularly according to a 0, 1, 6 month vaccination schedule.